What is the recommended treatment for a patient with an Abnormal Involuntary Movement Scale (AIMS) score of 3 (moderate tardive dyskinesia)?

Treatment for AIMS Score of 3 (Moderate Tardive Dyskinesia)

Treat with a VMAT2 inhibitor (valbenazine or deutetrabenazine) immediately, as the American Psychiatric Association recommends (1B level) that patients with moderate to severe or disabling tardive dyskinesia receive VMAT2 inhibitor therapy. 1

Understanding the Clinical Context

An AIMS score of 3 indicates moderate severity in at least one body region. This threshold is clinically significant because:

• Research demonstrates that VMAT2 inhibitors achieve meaningful improvement with a minimal clinically important change (MCIC) of approximately -2 points on the AIMS total motor score 2
• Moderate TD (score ≥3) meets the criteria used in pivotal trials that established VMAT2 inhibitor efficacy 3, 4
• Early treatment is crucial because the risk of TD becoming permanent increases with duration 5

Specific Treatment Algorithm

First-Line: VMAT2 Inhibitors

Choose between two FDA-approved options:

1. Valbenazine: Start at 40 mg/day, can increase to 80 mg/day after one week if tolerated

   • 80 mg/day shows superior efficacy with medium-to-high effect size (d = 0.89) 4
   • 66% of patients achieve ≥2-point improvement on AIMS 2
   • Number needed to treat ranges from 3-9 depending on response threshold 4

2. Deutetrabenazine: Titrate to effective dose (typically 12-48 mg/day in divided doses)

   • Achieved mean AIMS reduction of -3.0 points vs -1.6 for placebo at 12 weeks 3
   • 48.2% treatment success rate on Clinical Global Impression of Change 3

The evidence favors starting with valbenazine 80 mg/day if the patient can tolerate it, as this dose demonstrates the strongest efficacy without significant differences in adverse events compared to 40 mg/day 6. However, starting at 40 mg/day and titrating up is reasonable for tolerability concerns.

Concurrent Antipsychotic Management

While initiating VMAT2 inhibitor therapy, simultaneously address the causative agent:

• Reduce the antipsychotic dose to the minimum effective level for psychiatric stability
• Consider switching to a lower-risk second-generation antipsychotic (though this alone is insufficient for moderate TD)
• Do NOT use anticholinergics - these worsen TD despite potentially helping parkinsonism 5
• Continue the antipsychotic if needed for psychiatric stability; VMAT2 inhibitors work alongside ongoing antipsychotic therapy 1

Critical Pitfalls to Avoid

1. Waiting to treat: Some clinicians observe mild TD without intervention, but moderate severity (score ≥3) warrants immediate pharmacological treatment given permanence risk 5

2. Confusing TD with parkinsonism: Anticholinergic treatment for presumed parkinsonism will worsen TD. Use AIMS systematically to differentiate 5

3. Stopping antipsychotics abruptly: This risks psychiatric decompensation without guaranteed TD improvement. VMAT2 inhibitors allow continued psychiatric treatment 1

4. Underdosing VMAT2 inhibitors: The evidence clearly shows valbenazine 80 mg/day outperforms 40 mg/day for AIMS improvement and treatment response, with similar tolerability profiles 6

Monitoring and Follow-up

• Reassess AIMS at 6 weeks and 12 weeks to quantify treatment response
• Target ≥2-point reduction in AIMS total motor score as clinically meaningful improvement 2
• Monitor for psychiatric adverse events (anxiety, depression, suicidal ideation), though rates are low with VMAT2 inhibitors (1.7-3.4%) 3
• Check for parkinsonism using standardized scales, though VMAT2 inhibitors typically don't worsen motor function 3

When VMAT2 Inhibitors Are Insufficient

If inadequate response after 12 weeks at optimal VMAT2 inhibitor dosing:

• Verify medication adherence
• Reassess antipsychotic regimen for further dose reduction or switching
• Consider deep brain stimulation for treatment-resistant cases 7
• Ensure comprehensive multidisciplinary support for functional impairment

The strength of this recommendation rests on Level 1B guideline evidence from the APA 1 combined with robust randomized controlled trial data demonstrating both statistical significance and clinically meaningful improvements in TD symptoms with VMAT2 inhibitors 3, 4.